UA115052C2 - Конденсоване біциклічне 2,4-діамінопіримідинове похідне як подвійний alk- i fak-інгібітор - Google Patents

Конденсоване біциклічне 2,4-діамінопіримідинове похідне як подвійний alk- i fak-інгібітор

Info

Publication number
UA115052C2
UA115052C2 UAA201410832A UAA201410832A UA115052C2 UA 115052 C2 UA115052 C2 UA 115052C2 UA A201410832 A UAA201410832 A UA A201410832A UA A201410832 A UAA201410832 A UA A201410832A UA 115052 C2 UA115052 C2 UA 115052C2
Authority
UA
Ukraine
Prior art keywords
condensed bicyclic
fak inhibitor
diaminopyrimidine derivative
alk
dual alk
Prior art date
Application number
UAA201410832A
Other languages
English (en)
Ukrainian (uk)
Inventor
Лоран Курвуазьє (померлий)
Мартін Дж. Джейкобс
Грегорі Р. Отт
Шон П. Оллвейн
Original Assignee
Сефалон, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47892060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA115052(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сефалон, Інк. filed Critical Сефалон, Інк.
Publication of UA115052C2 publication Critical patent/UA115052C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
UAA201410832A 2012-03-06 2013-03-06 Конденсоване біциклічне 2,4-діамінопіримідинове похідне як подвійний alk- i fak-інгібітор UA115052C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607305P 2012-03-06 2012-03-06
PCT/US2013/029304 WO2013134353A1 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor

Publications (1)

Publication Number Publication Date
UA115052C2 true UA115052C2 (uk) 2017-09-11

Family

ID=47892060

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201410832A UA115052C2 (uk) 2012-03-06 2013-03-06 Конденсоване біциклічне 2,4-діамінопіримідинове похідне як подвійний alk- i fak-інгібітор

Country Status (28)

Country Link
US (5) US9132128B2 (OSRAM)
EP (2) EP3056494B1 (OSRAM)
JP (2) JP6016953B2 (OSRAM)
KR (1) KR102068374B1 (OSRAM)
CN (2) CN104159894B (OSRAM)
AU (1) AU2013229995B2 (OSRAM)
CA (1) CA2865420C (OSRAM)
CL (1) CL2014002353A1 (OSRAM)
CY (1) CY1117565T1 (OSRAM)
DK (1) DK2822939T3 (OSRAM)
EA (2) EA025859B1 (OSRAM)
ES (2) ES2570976T3 (OSRAM)
HR (1) HRP20160387T1 (OSRAM)
HU (1) HUE027976T2 (OSRAM)
IL (2) IL234239A (OSRAM)
ME (1) ME02460B (OSRAM)
MX (2) MX347772B (OSRAM)
MY (1) MY177290A (OSRAM)
NZ (1) NZ630251A (OSRAM)
PH (1) PH12014501979A1 (OSRAM)
PL (1) PL2822939T3 (OSRAM)
RS (1) RS54689B1 (OSRAM)
SG (2) SG10201507865QA (OSRAM)
SI (1) SI2822939T1 (OSRAM)
SM (1) SMT201600134B (OSRAM)
UA (1) UA115052C2 (OSRAM)
WO (1) WO2013134353A1 (OSRAM)
ZA (1) ZA201406147B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA115052C2 (uk) * 2012-03-06 2017-09-11 Сефалон, Інк. Конденсоване біциклічне 2,4-діамінопіримідинове похідне як подвійний alk- i fak-інгібітор
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2016105529A1 (en) 2014-12-23 2016-06-30 Cephalon, Inc. Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives
MX2021001398A (es) 2018-08-07 2021-08-16 In3Bio Ltd Métodos y composiciones para la inhibición de la vía egf/egfr en combinación con inhibidores de la cinasa del linfoma anaplásico.
WO2024178339A2 (en) * 2023-02-23 2024-08-29 The Regents Of The University Of Michigan Methods for treating neuroblastoma with a dual anaplastic lymphoma kinase and focal adhesion kinase inhibitor
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
JP4607879B2 (ja) 2003-08-15 2011-01-05 ノバルティス アーゲー 新生物疾患、炎症および免疫障害の処置に有用な2,4−ピリミジンジアミン
PL1713806T3 (pl) * 2004-02-14 2013-09-30 Irm Llc Związki i kompozycje jako inhibitory kinaz białkowych
AU2005230847B2 (en) 2004-03-31 2012-11-08 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US8962643B2 (en) * 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
JP5512274B2 (ja) * 2006-10-23 2014-06-04 セファロン、インク. ALK阻害剤およびc−MET阻害剤としての2,4−ジアミノピリミジンの縮合二環式誘導体
RS53588B1 (sr) * 2006-12-08 2015-02-27 Irm Llc Jedinjenja i kompozicije kao inhibitori protein kinaza
JP4782239B2 (ja) * 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク 異常細胞増殖治療のためのスルホニルアミド誘導体
HUE046402T2 (hu) * 2009-06-10 2020-03-30 Chugai Pharmaceutical Co Ltd Tetraciklusos vegyületek
UA115052C2 (uk) * 2012-03-06 2017-09-11 Сефалон, Інк. Конденсоване біциклічне 2,4-діамінопіримідинове похідне як подвійний alk- i fak-інгібітор
KR101446742B1 (ko) * 2012-08-10 2014-10-01 한국화학연구원 N2,n4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2016105529A1 (en) * 2014-12-23 2016-06-30 Cephalon, Inc. Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives

Also Published As

Publication number Publication date
AU2013229995B2 (en) 2017-04-13
EP2822939A1 (en) 2015-01-14
EA201691574A1 (ru) 2017-03-31
CN106166155A (zh) 2016-11-30
CN106166155B (zh) 2019-01-18
HK1205119A1 (zh) 2015-12-11
SG11201405371PA (en) 2014-09-26
EA025859B1 (ru) 2017-02-28
ES2570976T3 (es) 2016-05-23
CA2865420A1 (en) 2013-09-12
CL2014002353A1 (es) 2015-01-09
SG10201507865QA (en) 2015-10-29
RS54689B1 (sr) 2016-08-31
US10111872B2 (en) 2018-10-30
IL234239A (en) 2017-06-29
EA201491641A1 (ru) 2015-04-30
CY1117565T1 (el) 2017-04-26
CN104159894A (zh) 2014-11-19
US20190328735A1 (en) 2019-10-31
MY177290A (en) 2020-09-10
HRP20160387T1 (hr) 2016-05-20
KR102068374B1 (ko) 2020-01-20
PH12014501979B1 (en) 2014-11-24
SMT201600134B (it) 2016-07-01
US10632119B2 (en) 2020-04-28
PH12014501979A1 (en) 2014-11-24
EP2822939B1 (en) 2016-02-17
AU2013229995A1 (en) 2014-09-25
MX347772B (es) 2017-05-12
US9339502B2 (en) 2016-05-17
PL2822939T3 (pl) 2016-08-31
HUE027976T2 (en) 2016-11-28
CN104159894B (zh) 2016-09-07
CA2865420C (en) 2020-06-02
US20170173017A1 (en) 2017-06-22
MX372740B (es) 2020-05-04
EP3056494B1 (en) 2018-05-02
KR20140138247A (ko) 2014-12-03
JP2015509540A (ja) 2015-03-30
NZ630251A (en) 2016-02-26
ES2681487T3 (es) 2018-09-13
JP2017039741A (ja) 2017-02-23
US20160243119A1 (en) 2016-08-25
US20150374693A1 (en) 2015-12-31
IL252364B (en) 2018-03-29
MX2014010613A (es) 2014-09-18
ZA201406147B (en) 2015-12-23
WO2013134353A1 (en) 2013-09-12
SI2822939T1 (sl) 2016-04-29
US9623026B2 (en) 2017-04-18
EA033124B1 (ru) 2019-08-30
DK2822939T3 (en) 2016-03-14
WO2013134353A8 (en) 2014-06-19
US20150011561A1 (en) 2015-01-08
US9132128B2 (en) 2015-09-15
ME02460B (me) 2017-02-20
HK1226300A1 (zh) 2017-09-29
EP3056494A1 (en) 2016-08-17
JP6016953B2 (ja) 2016-10-26
IL252364A0 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
UA115052C2 (uk) Конденсоване біциклічне 2,4-діамінопіримідинове похідне як подвійний alk- i fak-інгібітор
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
PH12015500689A1 (en) Azaquinazoline inhibitors of atypical protein kinase c
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
MX2015005015A (es) Inhibidores heteroarilo de pde4.
EA201500362A1 (ru) Ингибиторы rho-киназы
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MX393499B (es) Derivados de pirazolopirimidina como inhibidor de cinasa
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
WO2014153100A3 (en) Arginine methyltransferase inhibitors and uses thereof
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MY199894A (en) Prmt5 inhibitors and uses thereof
WO2014153235A3 (en) Arginine methyltransferase inhibitors and uses thereof
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
MX2015012850A (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
TR201816379T4 (tr) DNA-PK inhibitörleri.
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
IN2014CN04558A (OSRAM)
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EP2595482A4 (en) ALDOSTERONSYNTHASEHEMMER
MX373320B (es) Compuestos inhibidores de pde2.
MX2017000521A (es) Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde4.
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения
MX366840B (es) Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde.
MX2015013936A (es) Compuestos de pirimidina condensada sustituida.